What is the recommended monthly intramuscular dosing for Abilify (aripiprazole)?

Abilify Intramuscular Monthly Dosing

The recommended monthly intramuscular dose of Abilify (aripiprazole once-monthly, AOM 400) is 400 mg administered once every 4 weeks via gluteal or deltoid injection, with 14 days of concurrent oral aripiprazole (10-15 mg/day) following the first injection. 1

Initiation Regimen

Standard Single-Injection Start

• First injection: 400 mg IM (gluteal or deltoid)
• Concurrent oral therapy: Continue oral aripiprazole 10-15 mg/day for 14 days after the first injection
• Subsequent injections: 400 mg every 4 weeks (monthly) without oral supplementation 1

Alternative Two-Injection Start (Simplified Option)

• Day 1: Two separate 400 mg injections at different sites (gluteal and/or deltoid) PLUS a single oral dose of aripiprazole 20 mg
• No 14-day oral overlap required with this regimen
• This approach provides comparable pharmacokinetic profiles to the standard regimen while eliminating the need for daily oral administration 2, 3

Maintenance Dosing

Continue 400 mg IM every 4 weeks indefinitely. The 400 mg dose is both the starting and maintenance dose—no titration is needed 1, 4. Clinical trial data show that 90.1% of patients (1,296/1,439) required no dose adjustment from the initial 400 mg dose 4.

Dose Adjustment

• A single dose reduction to 300 mg monthly is permitted if tolerability issues arise 5
• Doses higher than 400 mg have not been systematically studied for the monthly formulation

Key Clinical Considerations

Switching from Oral Aripiprazole

• If patient is stabilized on oral aripiprazole (10-30 mg/day), initiate AOM 400 and continue the same oral dose for 14 days
• The efficacy and safety are comparable regardless of whether patients were previously on 10 mg or 30 mg oral doses 4

Switching from Other Antipsychotics

• Cross-titration period >1 to 4 weeks is superior to ≤1 week when switching from other oral antipsychotics to oral aripiprazole before initiating AOM 400
• Longer cross-titration (>1-4 weeks) resulted in lower discontinuation rates due to adverse events (2.7% vs 10.4%) 4
• Target oral aripiprazole dose of 10-30 mg/day during cross-titration

Pharmacokinetic Profile

• Therapeutic aripiprazole plasma concentrations (≥95 ng/mL) are reached within 7 days of the first injection 4
• The 14-day oral overlap accounts for interpatient variability to ensure all patients achieve therapeutic levels
• Mean plasma concentration after 4 weeks: 93-112 ng/mL (within therapeutic window of 94.0-534.0 ng/mL) 4

Injection Site Specifics

• Approved sites: Gluteal or deltoid muscle 1
• Both sites provide similar pharmacokinetic profiles for the 400 mg dose 2
• Critical: The 1064 mg dose of aripiprazole lauroxil (a different formulation) should ONLY be given gluteally—deltoid administration of this higher dose results in altered pharmacokinetics 6

Efficacy Data

AOM 400 demonstrated:

• Significantly delayed time to relapse versus placebo (hazard ratio 5.03,95% CI 3.15-8.02) 5
• Relapse rate of only 10.0% versus 39.6% with placebo over 52 weeks 5
• Rapid symptom stabilization maintained long-term across multiple studies 7
• Low discontinuation rates due to lack of efficacy (2.3%-10.0% across studies) 4

Common Pitfalls to Avoid

1. Don't skip the 14-day oral overlap with standard single-injection start—this ensures therapeutic coverage during the absorption phase
2. Don't use doses other than 400 mg for initiation—this is the established starting dose supported by pharmacokinetic data
3. Don't rush cross-titration when switching from other antipsychotics—allow >1 to 4 weeks for better tolerability
4. Don't confuse formulations—aripiprazole once-monthly (AOM) 400 mg is different from aripiprazole lauroxil, which has different dosing schedules and site requirements

The two-injection start regimen offers a practical alternative that eliminates the burden of 14 days of oral medication, potentially improving early adherence while maintaining equivalent safety and efficacy 2, 3.